News

Pilot Study May Lead to Telemedicine Benefiting People with Multiple Sclerosis

Telemedicine, which allows healthcare professionals to evaluate, diagnose and treat patients at a distance with telecommunications technology, may soon benefit people with multiple sclerosis (MS). Elizabeth Morrison-Banks, MD, a health sciences clinical professor at theĀ University of California at RiversideĀ School of Medicine,Ā is planning a pilot one-year study of a home-based…

MS Views and News to Host ‘MS Champions’ Gala on April 22 in Florida

MS Views and News, aĀ non-profit multiple sclerosis (MS) advocacy organization,Ā will host its second annual Champions Tackling MS Gala on April 22, with money raised goingĀ to support live educational events, community resources, and services intended to help improve the quality of life for peopleĀ with MS. The Saturday event at the…

Clinical Test of Rex Robotic Device as Rehabilitation Aid for MS Patients Starting in UK

A clinical test of whether bionic robotics can improveĀ mobilityĀ in peopleĀ with relapsing orĀ progressive forms of multiple sclerosis (MS) and considerable disability is now recruiting participants, after being approved by the U.K. National Health Service’s Health Research Authority (HRA) ethics committee. The trial, called RAPPER 3Ā (Robot Assisted Physiotherapy Exercises with Rex…

Australians Living with MS Lack Adequate Oral Care, Study Finds

Australians living with multiple sclerosis (MS) don’t haveĀ adequate access to dental care, a new study reports. The study, ā€œHow do Australians living with MS experience oral health and accessing dental care? A focus group study,ā€ appearedĀ in the journalĀ Community Dentistry and Oral Epidemiology. MS is an autoimmune…

#ACTRIMS2017 – MS, the Gut and Probiotics

Harold Weiner, MD, believes in using probiotics to help treat multiple sclerosis.Ā He is such a believer that he did a presentation on the subject ā€” “Probiotics in Multiple Sclerosis” ā€” at the just-concluded Americas for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum in Orlando. The event…

Full Transcript of Interview with Genentech’s Medical Director, Peter Chin, on Ocrevus

BelowĀ is a transcript of theĀ Multiple Sclerosis News TodayĀ interview with Dr. Peter Chin ā€” principal medical director at Genentech ā€” about the importance of the pending U.S. Food and Drug Administration (FDA) approval of a Biologics Licensing Application (BLA) for Ocrevus (ocrelizumab). An an indepth article on this interview,Ā lookingĀ Ocrevus…

#ACTRIMS2017 – Study Reports Possible Link Between Viral Infections, Vitamin D, and Risk for MS

In a U.S. nationwideĀ case study, a team of researchers found evidence forĀ a potential link between viralĀ infections during childhood, vitamin D deficiency, and the risk of developingĀ multiple sclerosis (MS). The study, ā€œEnvironmental risk factors associated with pediatric MS: The role of remote viral infections and vitamin D revisited,ā€ was recently…

#ACTRIMS2017 – Ocrevus Significantly Decreases Disease Activity in MS Patients, Study Shows

Ocrevus (ocrelizumab), an investigational monoclonal antibody, significantly decreases disease activity in patients with multiple sclerosis (MS), and is associated with a higher proportion of patients reaching no evidence of disease activity (NEDA), according to a new analysis. The study,Ā ā€œNEDA analysis by epoch in patients with relapsing multiple…

#ACTRIMS2017 – Novantrone Lowers Relapse Rates over Long Term, But Carries Cancer Risk

Ten years after completingĀ treatment with Novantrone (mitoxantrone), a chemotherapy drug, multiple sclerosis (MS) patients showed evidence of markedly lowerĀ annualized relapse rates, but the therapy’s effects began to wane after five years, a studyĀ presented atĀ ACTRIMS 2017 ForumĀ reported. The study also assessed howĀ Novantrone affects disease progression in primary and secondary progressive…